Multiple Myeloma (Kahler Disease) (Oncology) – Drugs in Development, 2021
- Pages: 2980
- Published: December 2021
- Report Code: GMDHC13205IDB
Global Markets Direct’s, ‘Multiple Myeloma (Kahler Disease) – Drugs In Development, 2021’, provides an overview of the Multiple Myeloma (Kahler Disease) pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Multiple Myeloma (Kahler Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Multiple Myeloma (Kahler Disease) and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
– The report provides a snapshot of the global therapeutic landscape of Multiple Myeloma (Kahler Disease)
– The report reviews pipeline therapeutics for Multiple Myeloma (Kahler Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources
– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
– The report reviews key players involved Multiple Myeloma (Kahler Disease) therapeutics and enlists all their major and minor projects
– The report assesses Multiple Myeloma (Kahler Disease) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
– The report summarizes all the dormant and discontinued pipeline projects
– The report reviews latest news related to pipeline therapeutics for Multiple Myeloma (Kahler Disease)
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Multiple Myeloma (Kahler Disease)
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Multiple Myeloma (Kahler Disease) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Companies mentioned
4SC AG
A. Menarini Industrie Farmaceutiche Riunite Srl
Aadi Bioscience Inc
Abbisko Therapeutics Co Ltd
AbbVie Inc
Abcuro Inc
ABL Bio Inc
Actinium Pharmaceuticals Inc
Active Biotech AB
Adicet Bio Inc
Aeglea BioTherapeutics Inc
Affimed GmbH
AGC Biologics SpA
Allife Medical Science and Technology Co Ltd
Allogene Therapeutics Inc
Alphamab Oncology
Ambrx Biopharma Inc
Amgen Inc
Anaveon AG
Antaimmu BioMed Co Ltd
Antengene Corp Ltd
Antion Biosciences SA
APIM Therapeutics AS
APO-T BV
Arcellx Inc
Arch Oncology Inc
Arcus Biosciences Inc
Ariz Precision Medicine Inc
Arjuna Therapeutics
Arovella Therapeutics Ltd
Ascenta Therapeutics Inc
Ascentage Pharma Group International
Asclepius Technology Company Group Suzhou Co Ltd
Aslan Pharmaceuticals Ltd
AstraZeneca Plc
Asylia Therapeutics Inc
Auransa Inc
Aurigene Discovery Technologies Ltd
Autolus Therapeutics Plc
Avalo Therapeutics Inc
Ayala Pharmaceuticals Inc
Bantam Pharmaceutical LLC
Bayer AG
BeiGene Ltd
Beijing Immunochina Pharmaceuticals Co Ltd
Beijing Menlo Biotechnology Co Ltd
Beijing Sunbio Biotech Co Ltd
Bellicum Pharmaceuticals Inc
Betta Pharmaceuticals Co Ltd
BeyondSpring Inc
Biocad
BioCurate Pty Ltd
BioLineRx Ltd
Biomea Fusion Inc
Biosion Inc
BioVec Pharma Inc
BioVie Inc
Bivictrix Therapeutics PLC
bluebird bio Inc
Boehringer Ingelheim International GmbH
Bristol-Myers Squibb Co
C4 Therapeutics Inc
Calithera Biosciences Inc
CanBas Co Ltd
Cantex Pharmaceuticals Inc
Carbiogene Therapeutics Co Ltd
Caribou Biosciences Inc
CARsgen Therapeutics Ltd
Cartesian Therapeutics Inc
CASI Pharmaceuticals Inc
CDR-Life Inc
Cell Source Inc
CellCentric Ltd
Cellectar Biosciences Inc
Cellectis SA
Celleron Therapeutics Ltd
Cellestia Biotech AG
Cello Therapeutics Inc
Cellular Biomedicine Group Inc
Celularity Inc
Celyad Oncology SA
Centrax International Inc
Ceptur Therapeutics Inc
Checkpoint Therapeutics Inc
Cheetah Cell Therapeutics Co Ltd
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Chimerix Inc
China Immunotech (Beijing) Biotechnology Co Ltd
Chinook Therapeutics Inc
Chong Kun Dang Pharmaceutical Corp
Chongqing Precision Biotech Co Ltd
CiMaas BV
Cleave Therapeutics Inc
Compugen Ltd
Convalife
Corvus Pharmaceuticals Inc
CRISPR Therapeutics AG
CSPC Pharmaceutical Group Ltd
CStone Pharmaceuticals Co Ltd
Curocell Inc
Cyclacel Pharmaceuticals Inc
Cyteir Therapeutics Inc
Cytovia Therapeutics Inc
Daiichi Sankyo Co Ltd
DeuteRx LLC
DexTech Medical AB
Diverse Biotech Inc
Eli Lilly and Co
Elpis Biopharmaceuticals Corp
EpicentRx Inc
EpimAb Biotherapeutics Inc
Epizyme Inc
Eternity Bioscience Inc
eTheRNA Immunotherapies NV
Eureka Therapeutics Inc
EUSA Pharma (UK) Ltd
ExCellThera Inc
Exelixis Inc
F. Hoffmann-La Roche Ltd
Fate Therapeutics Inc
Fera Pharmaceuticals LLC
Fortis Therapeutics Inc
Fusion Pharmaceuticals Inc
Gadeta BV
Galileo Research srl
Gamida Cell Ltd
GEMoaB Monoclonals GmbH
GemoPharm
Genenta Science srl
Genentech USA Inc
Genmab AS
Geron Corp
Gilead Sciences Inc
GlaxoSmithKline Plc
Gliknik Inc
GlycoMimetics Inc
Glycostem Therapeutics BV
GlyTR Therapeutics Inc
GP Pharm SA
Gracell Biotechnologies Inc
GT Biopharma Inc
Guangdong Zhongsheng Pharmaceutical Co Ltd
Guangzhou Bio-gene Technology Co Ltd
HaemaLogix Pty Ltd
Hangzhou DAC Biotech Co Ltd
Hangzhou Sumgen Biotech Co Ltd
Harbin Gloria Pharmaceuticals Co Ltd
Harbour BioMed (Guangzhou) Co Ltd
Harpoon Therapeutics Inc
Hebei Senlang Biotechnology Co Ltd
Heidelberg Pharma AG
Helix BioPharma Corp
Helocyte Biosciences Inc
Hengenix Biotech Inc
Hinova Pharmaceuticals Co Ltd
HitGen Inc
Holy Stone Healthcare Co Ltd
HRAIN Biotechnology Co Ltd
Hummingbird Bioscience Pte Ltd
Hunan Siweikang Therapeutics Ltd
HuniLife Biotechnology Inc
Hutchison MediPharma Ltd
I-Mab
iCell Gene Therapeutics LLC
Ichnos Sciences Inc
IDAC Theranostics Inc
IDP Discovery Pharma SL
IGM Biosciences Inc
Immix BioPharma Inc
ImmuneCyte Inc
ImmuneOnco Biopharmaceuticals (Shanghai) Co Ltd
ImmuneTarget Inc
Immunicum AB
ImmunityBio Inc
Immunotech Biopharm Ltd
Immunwork Inc
Incyte Corp
Indapta Therapeutics Inc
Inflection Biosciences Ltd
Inmune Bio Inc
InnoCare Pharma Ltd
Innovative Cellular Therapeutics Co Ltd
Intra-Immusg Pvt Ltd
Inventiva SA
IO Biotech Inc
Io Therapeutics Inc
Ionis Pharmaceuticals Inc
Ionova Life Science Co Ltd
Istesso Ltd
iTeos Therapeutics Inc
Iterion Therapeutics Inc
Jiangsu Carephar Pharmaceutical Co Ltd
Jiangsu Chai Tai Fenghai Pharmaceutical Co Ltd
Jiangsu Hansoh Pharmaceutical Group Co Ltd
Jiangsu Zhengda Fenghai Pharmaceutical Co Ltd
Jiangxi Shanxing Biotechnology Co Ltd
JN Biosciences LLC
Johnson & Johnson
JSK Therapeutics Inc
Jubilant Therapeutics Inc
Juventas Cell Therapy Ltd
JW Pharmaceutical Corp
K36 Therapeutics Inc
Kangpu Biopharmaceuticals Ltd
Karyopharm Therapeutics Inc
KeyMed Biosciences Inc
Kiadis Pharma NV
KisoJi Biotechnology Inc
Klyss Biotech Inc
Kodikaz Therapeutic Solutions Inc
Komipharm International Co Ltd
Kronos Bio Inc
KYAN Therapeutics Inc
Kymab Ltd
Laekna Therapeutics Shanghai Co Ltd
LAVA Therapeutics NV
Leadiant Biosciences Inc
Legend Biotech Corp
Les Laboratoires Servier SAS
Leukogene Therapeutics Inc
Ligand Pharmaceuticals Inc
LintonPharm Co Ltd
Lokon Pharma AB
Loxo Oncology Inc
Luminus Biosciences Inc
Luye Pharma Group Ltd
Mablink Bioscience
Machavert Pharmaceuticals LLC
Marker Therapeutics Inc
Max Biopharma Inc
MediGene AG
MedPacto Inc
Merck & Co Inc
Millennium Pharmaceuticals Inc
Miltenyi Biotec BV & Co KG
MimiVax LLC
MiNK Therapeutics Inc
Modulation Therapeutics Inc
Molecular Partners AG
Molecular Templates Inc
Morphogenesis Inc
MorphoSys AG
Multitude therapeutics Inc
Mustang Bio Inc
Mycovia Pharmaceuticals Inc
Nanexa AB
Nanjing Aimeifei Biomedical Technology Co Ltd
Nanjing Bioheng Biotech Co Ltd
Nanjing Iaso Biotherapeutics Co Ltd
Nektar Therapeutics
Neoleukin Therapeutics Inc
Neomics Pharmaceuticals LLC
Neonc Technologies Inc
Nerviano Medical Sciences SRL
Newave Pharmaceutical Inc
NewBay Medical Technology Co Ltd
NexImmune Inc
Northlake International LLC
Novartis AG
Oncodesign SA
OncoFusion Therapeutics Inc
Oncolytics Biotech Inc
OncoMyx Therapeutics Inc
Onconova Therapeutics Inc
OncoPep Inc
Oncopeptides AB
OncoTartis Inc
OncoTherapy Science Inc
One World Cannabis Ltd
ONK Therapeutics Ltd
Ono Pharmaceutical Co Ltd
Onward Therapeutics SA
Orgenesis Inc
ORIC Pharmaceuticals Inc
Origincell Technology Group Co Ltd
Otsuka Pharmaceutical Co Ltd
Paras Biopharmaceuticals Finland Oy
PentixaPharm GmbH
PersonGen Anke Cellular Therapeutics Co Ltd
PersonGen Biomedicine Suzhou Co Ltd
Pfizer Inc
Pharma Mar SA
Phi Pharma SA
Phosplatin Therapeutics LLC
PI Therapeutics Ltd
Pimera Inc
Pinotbio Inc
Poseida Therapeutics Inc
Precision Biosciences Inc
Pregene ShenZhen Biotechnology Co Ltd
Prelude Therapeutics Inc
Prescient Therapeutics Ltd
Protheragen Inc
Qilu Pharmaceutical Co Ltd
Quadriga BioSciences Inc
Qwixel Therapeutics LLC
Rapa Therapeutics LLC
RAPT Therapeutics Inc
Raqia Therapeutics Inc
Regeneron Pharmaceuticals Inc
RESTEM
SA Science Inc
Sana Biotechnology Inc
Sanofi
Seagen Inc
SELLAS Life Sciences Group Inc
Senhwa Biosciences Inc
Shandong New Time Pharmaceutical Co Ltd
Shanghai Biomed-Union Biotechnology Co Ltd
Shanghai Bioray Laboratory Inc
Shanghai GeneChem Co Ltd
Shanghai Junshi Bioscience Co Ltd
Shanghai Keqi Pharmaceutical Technology Co Ltd
Shanghai Novamab Biopharmaceuticals Co Ltd
Shanghai Theorion Pharmaceutical Co Ltd
Shanghai Unicar-Therapy Bio-Medicine Technology Co Ltd
Shanghai YaKe Biotechnology Co Ltd
Shanghai Yingli Pharmaceutical Co Ltd
Shenogen Pharma Group Ltd
Shenzhen Chipscreen Biosciences Co Ltd
Shenzhen Neptunus Institute of Pharmaceutical Technology Co Ltd
Shenzhen Targetrx Inc
Shuttle Pharmaceuticals Inc
Sichuan Kelun Bio-Tech Pharmaceutical Co Ltd
Sichuan Kelun Pharmaceutical Co Ltd
SignalRx Pharmaceuticals Inc
SignPath Pharma Inc
Sorrento Therapeutics Inc
SpecificiT Pharma Inc
Sphaera Pharma Pte Ltd
SpringWorks Therapeutics Inc
Starton Therapeutics Inc
Sumitomo Dainippon Pharma Oncology, Inc
Sunnycell Therapeutics Ltd
Sunomix Therapeutics
Surface Oncology Inc
Sutro Biopharma Inc
Suzhou Maximum Bio-tech Co Ltd
Synactix Pharmaceuticals Inc
SynDevRx Inc
T-Cure Bioscience Inc
T-CURX GmbH
Taiho Oncology Inc
TaiRx Inc
Takeda Pharmaceutical Co Ltd
Targazyme Inc
Telix Pharmaceuticals Ltd
Tianweiyuan and Biomedicine Shanghai Co Ltd
TiCARos Co Ltd
Tiziana Life Sciences Plc
Tmunity Therapeutics Inc
Transgene Biotek Ltd
Triterpenoid Therapeutics Inc
Triumvira Immunologics Inc
TSD Life Sciences
TTY Biopharm Co Ltd
Ube Industries Ltd
Up Therapeutics Inc
VaxcellBio Inc
Vaxil Bio Therapeutics Ltd
Verastem Inc
Vichem Chemie Research Ltd
Vincerx Pharma Inc
Visterra Inc
Vycellix Inc
Vyriad Inc
Wellington Zhaotai Therapies Ltd
Wigen Biomedicine Technology (Shanghai) Co Ltd
WindMIL Therapeutics Inc
Wugen Inc
Wuhan Bio-Raid Biotechnology Co Ltd
Wuhan YZY Biopharma Co Ltd
XBiotech Inc
XEME BioPharma Inc
Xencor Inc
Xi'An Yufan Biotechnology Co Ltd
Xiangxue Life Sciences
XNK Therapeutics AB
Zhengda Tianqing Pharmaceutical Group Co Ltd
Zovis Pharmaceuticals
Zymergen Inc
Table of Contents
List of Tables
List of Figures
Pricing
Discounts available for multiple purchases.